Narrative review / 2017
A review concludes red yeast rice is not an acceptable substitution for statins due to variability in monacolin K, unknown risks, and potential toxicity.
This review evaluates the therapeutic and side effects of red yeast rice, a supplement containing Monascus purpureus and monacolin K (chemically identical to lovastatin). The author reports that red yeast rice preparations exhibit large variability in monacolin K concentration and types, making dose-related efficacy and side-effect risks practically impossible to predict. Additionally, other ingredients in red yeast rice are potentially toxic, and the FDA has issued warnings due to lack of standardized preparations and safety assurances. Based on clinical trial results and literature, the author argues red yeast rice is not an acceptable substitution for statins.
- Study type
- Narrative review
- Who was studied
- Hypercholesterolemic patients
- What was measured
- Efficacy, side effects, variability in monacolin K content, and safety
THE PAPER
Red Yeast Rice Preparations: Are They Suitable Substitutions for Statins?
Dujovne CA. Am J Med, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.